Current Report Filing (8-k)
31 Mai 2017 - 11:16PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of
1934
Date of
Report (Date of Earliest Event Reported): May 24, 2017
MetaStat, Inc.
(Exact
name of registrant as specified in its charter)
Nevada
(State
or other jurisdiction of incorporation)
|
000-52735
|
20-8753132
|
|
(Commission File
Number)
|
(IRS Employer
Identification No.)
|
27 DryDock Avenue, 2
nd
Floor
Boston, MA 02210
(Address of
principal executive offices and zip code)
(212) 796-8170
(Registrant's
telephone number including area code)
(Registrant's
former name or former address, if changed since last
report)
Check the appropriate box be
low
if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of registrant under any of the following
provisions:
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12(b) under the Exchange
Act (17 CFR 240.14a-12(b))
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02.
|
Departure
Of Directors Or Certain Officers; Election Of Directors;
Appointment Of Certain Officers; Compensatory Arrangements of
Certain Officers.
|
Appointment of New Director:
Effective
as of May 24, 2017, the board of directors (the “
Board
”) of MetaStat, Inc.
(the “
Company
”) appointed Paul
Billings, M.D., Ph.D. to the Board.
Dr.
Billings was appointed to our board of directors effective as of
May 24, 2017. Dr. Billings is a board certified internist and
clinical geneticist. Dr. Billings is currently a partner at the
Bethesda Group Fund L.P., a position he has held since January
2016. From January 2015 to January 2016, Dr. Billings served as
Executive-in-Residence at the California Innovation Center of
Johnson and Johnson, Inc. He has also served as the Medical
Director of the IMPACT program at Thermo Fisher
Scientific, Inc. (TFS) from 2013 to 2015. From 2010 to 2014,
he served as the first and only Chief Medical Officer at Life
Technologies Corporation (which was acquired by TFS), and the
Genetic Sciences Division of TFS. Dr. Billings currently
serves on the board of directors of Trovagene, Inc. since October
2013, and Rennova Health, Inc. (formerly CollabRx, Inc.) since
November 2015. Dr. Billings has previously served as a director of
Ancestry.com Inc. from February 2012 to May 2013. He serves as an
advisor or director for many companies, including Fabric Genomics,
Inc. (formerly Omicia, Inc.), BioScale Inc., Applied Immunology,
Inc., Aueon, Inc. and PAX Neuroscience Inc. He held senior
management positions at Cord Blood Registry, Inc., GeneSage, Inc.,
Laboratory Corporation of America Holdings (LabCorp), and
CELLective DX Corporation. Dr. Billings’ clinical experience
includes senior administrative positions at El Camino Hospital and
the Veteran’s Administration and he served as a physician at
many medical centers. He has held numerous academic appointments at
prestigious universities including Harvard University, Stanford
University, U.C. Berkeley, and U.C. San Francisco. He is a prolific
author with nearly 200 publications and books on genomic medicine.
Dr. Billings holds an M.D. from Harvard Medical School and a
Ph.D. in immunology, also from Harvard
University. Dr. Billings is a nationally recognized
expert on genomic and precision medicine, and his extensive medical
and managerial experience in the field of personalized medicine
qualifies him to serve as our director.
Dr. Billings has no family relationship with any of the executive
officers or directors of the Company. There have been no
transactions in the past two years to which the Company or any of
its subsidiaries was or is to be a party, in which Dr. Billings
had, or will have, a direct or indirect material
interest.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
|
METASTAT,
INC.
|
|
|
|
|
|
|
|
|
By:
|
/s/
Douglas A.
Hamilton
|
|
|
|
|
Name:
Douglas
A. Hamilton
|
|
|
|
|
Title:
President and
CEO
|
|
|
Dated:
May 31, 2017
|
|
|
|
MetaStat (CE) (USOTC:MTST)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
MetaStat (CE) (USOTC:MTST)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024
